Focus: Zai Lab is a public biotech company developing small-molecule and biologic therapies across oncology, immunology, and rare disease indications. The company operates at commercial scale with $267M in FY2025 revenue and a diversified pipeline of 30 active programs.
Profile data last refreshed 19h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Zai Lab to get notified when they start hiring — the background below is worth knowing for when they do.
Lead marketed product with 11-year exclusivity runway; key revenue driver for company profitability trajectory.
Help build intelligence for Zai Lab
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Zai Lab's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic ANDA product with limited differentiation; marginal contribution to revenue.
Generic corticosteroid; limited growth potential and shrinking margins typical of post-LOE ANDA products.
Zai Lab Limited (ZLAB) Gains EMA Orphan Drug Designation for DLL3-Targeting Cancer Therapy - Yahoo Finance
Zai Lab Limited (ZLAB) Gains EMA Orphan Drug Designation for DLL3-Targeting Cancer Therapy Yahoo Finance
China is fretting over a demographic crisis – but what companies might benefit? - South China Morning Post
China is fretting over a demographic crisis – but what companies might benefit? South China Morning Post
Zai Lab’s zocilurtatug pelitecan secures EMA orphan drug status - Pharmaceutical Technology
Zai Lab’s zocilurtatug pelitecan secures EMA orphan drug status Pharmaceutical Technology
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas - Yahoo Finance
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas Yahoo Finance
Zai Lab gains European orphan drug designation - grafa.com
Zai Lab gains European orphan drug designation grafa.com
US launch milestone puts Zai Lab’s ZEJULA cancer pill in the spotlight - ad-hoc-news.de
US launch milestone puts Zai Lab’s ZEJULA cancer pill in the spotlight ad-hoc-news.de
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
An ambispective, observational real-world study of tumor-treating fields for treatment of Chinese patients with newly diagnosed or recurrent/progressive glioblastoma.
Tisotumab vedotin versus chemotherapy in Chinese patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo